Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-14T20:04:08.447Z Has data issue: false hasContentIssue false

33 - Botulinum Toxin Therapy for Cervical Dystonia

from Section II - Botulinum Toxin Therapy

Published online by Cambridge University Press:  31 May 2018

By
Mary Ann Thenganatt  and
Joseph Jankovic
Edited by
Dirk Dressler ,
Eckart Altenmüller  and
Joachim K. Krauss
Dirk Dressler
Affiliation:
Hannover Medical School
Eckart Altenmüller
Affiliation:
Hochschule für Musik, Theater und Medien, Hannover
Joachim K. Krauss
Affiliation:
Hannover Medical School
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Treatment of Dystonia , pp. 160 - 166
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albanese, A, Abbruzzese, G, Dressler, D, Duzynski, W, Khatkova, S, Marti, MJ, Mir, P, Montecucco, C, Moro, E, Pinter, M, Relja, M, Roze, E, Skogseid, IM, Timerbaeva, S, Tzoulis, C (2015). Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213.CrossRefGoogle ScholarPubMed
Baizabal-Carvallo, JF, Jankovic, J, Pappert, E (2011). Flu-like symptoms following botulinum toxin therapy. Toxicon 58:1–7.CrossRefGoogle ScholarPubMed
Baizabal-Carvallo, JF, Jankovic, J, Feld, J (2013). Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res 2:298–306.CrossRefGoogle Scholar
Benecke, R, Jost, WH, Kanovsky, P, Ruzicka, E, Comes, G, Grafe, S (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951.CrossRefGoogle ScholarPubMed
Bhidayasiri, R (2011). Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 17 (Suppl. 1):S20–S24.CrossRefGoogle ScholarPubMed
Brashear, A, Lew, MF, Dykstra, DD, Comella, CL, Factor, SA, Rodnitzky, RL, Trosch, R, Singer, C, Brin, MF, Murray, JJ, Wallace, JD, Willmer-Hulme, A, Koller, M (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53:1439–1446.CrossRefGoogle ScholarPubMed
Brin, MF, Lew, MF, Adler, CH, Comella, CL, Factor, SA, Jankovic, J, O’Brien, C, Murray, JJ, Wallace, JD, Willmer-Hulme, A, Koller, M (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53:1431–1438.CrossRefGoogle ScholarPubMed
Brin, MF, Comella, CL, Jankovic, J, Lai, F, Naumann, M; CD-017 BoNTA Study Group (2008). Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360.CrossRefGoogle ScholarPubMed
Burke, RE, Fahn, S, Marsden, CD (1986). Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36:160–164.CrossRefGoogle ScholarPubMed
Charles, D, Brashear, A, Hauser, RA, Li, HI, Boo, LM, Brin, MF; CD 140 Study Group (2012). Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 35:208–214.CrossRefGoogle Scholar
Charles, PD, Adler, CH, Stacy, M, Comella, C, Jankovic, J, Manack Adams, A, Schwartz, M, Brin, MF (2014). Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol 261:1309–1319.CrossRefGoogle ScholarPubMed
Comella, CL, Jankovic, J, Shannon, KM, Tsui, J, Swenson, M, Leurgans, S, Fan, W; Dystonia Study Group (2005). Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65:1423–1429.CrossRefGoogle Scholar
Comella, CL, Jankovic, J, Truong, DD, Hanschmann, A, Grafe, S; US XEOMIN Cervical Dystonia Study Group (2011). Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308:103–109.CrossRefGoogle Scholar
Comella, CL, Perlmutter, JS, Jinnah, HA, Waliczek, TA, Rosen, AR, Galpern, WR, Adler, CA, Barbano, RL, Factor, SA, Goetz, CG, Jankovic, J, Reich, SG, Rodriguez, RL, Severt, WL, Zurowski, M, Fox, SH, Stebbins, GT (2016). Clinimetric testing of the Comprehensive Cervical Dystonia Rating Scale (CCDRS). Mov Disord 31:563–569.CrossRefGoogle Scholar
Defazio, G, Jankovic, J, Giel, JL, Papapetropoulos, S (2013). Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (NY) 4:3.Google Scholar
Dressler, D (2000). Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 7:713–718.CrossRefGoogle ScholarPubMed
Dressler, D, Benecke, R (2003). Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38.CrossRefGoogle ScholarPubMed
Dressler, D, Bigalke, H (2004). Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 52:132–135.CrossRefGoogle ScholarPubMed
Dressler, D, Tacik, P, Saberi, FA (2015). Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm 122:297–300.CrossRefGoogle ScholarPubMed
Evidente, VG, Truong, D, Jankovic, J (2014). IncobotulinumtoxinA (Xeomin(R)) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci 346:116–120.CrossRefGoogle ScholarPubMed
Finsterer, J, Maeztu, C, Revuelta, G, Reichel, G, Truong, D (2015). Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci 355:37–43.CrossRefGoogle ScholarPubMed
Greene, P, Kang, U, Fahn, S, Brin, M, Moskowitz, C, Flaster, E. (1990). Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40:1213–1218.CrossRefGoogle ScholarPubMed
Hallett, M, Albanese, A, Dressler, D, Segal, KR, Simpson, DM, Truong, D, Jankovic, J (2013). Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114.CrossRefGoogle ScholarPubMed
Hanna, PA, Jankovic, J (1998). Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50:1624–1629.Google Scholar
Jankovic, J (2017). Botulinum toxin: state of the art. Mov Disod 32:1131–1138.CrossRefGoogle ScholarPubMed
Jankovic, J (2018). An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. Epub ahead of print.CrossRefGoogle ScholarPubMed
Jankovic, J, Hunter, C, Dolimbek, BZ, Dolimbek, GS, Adler, CH, Brashear, A, Comella, CL, Gordon, M, Riley, DE, Sethi, K, Singer, C, Stacy, M, Tarsy, D, Atassi, MZ (2006). Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67:2233–2235.CrossRefGoogle ScholarPubMed
Jankovic, J, Adler, CH, Charles, D, Comella, C, Stacy, M, Schwartz, M, Manack Adams, A, Brin, MF (2015). Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 349:84–93.CrossRefGoogle ScholarPubMed
Jindal, P, Jankovic, J (2017). Botulinum toxin treatment in Parkinson’s disease and atypical parkinsonian disorders. In Jabbari, Bahman (ed.) Botulinum Toxin Treatment. New York: Springer.Google Scholar
Jinnah, HA, Goodmann, E, Rosen, AR, Evatt, M, Freeman, A, Factor, S (2016). Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 263:1188–1194.CrossRefGoogle ScholarPubMed
Jost, WH, Benecke, R, Hauschke, D, Jankovic, J, Kaňovský, P, Roggenkämper, P, Simpson, DM, Comella, CL (2014). Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther 9:1913–1926.Google Scholar
Kilbane, C, Ostrem, J, Galifianakis, N, Grace, J, Markun, L, Glass, GA (2012). Multichannel electromyographic mapping to optimize onabotulinumtoxinA efficacy in cervical dystonia. Tremor Other Hyperkinet Mov (NY) 2.Google ScholarPubMed
Lew, MF, Adornato, BT, Duane, DD, Dykstra, DD, Factor, SA, Massey, JM, Brin, MF, Jankovic, J, Rodnitzky, RL, Singer, C, Swenson, MR, Tarsy, D, Murray, JJ, Koller, M, Wallace, JD (1997). Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49:701–707.CrossRefGoogle ScholarPubMed
Misra, VP, Ehler, E, Zakine, B, Maisonobe, P, Simonetta-Moreau, M; Interest in CD Group (2012). Factors influencing response to botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 14(2).Google Scholar
Mordin, M, Masaquel, C, Abbott, C, Copley-Merriman, C (2014). Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open 4:e005150.CrossRefGoogle ScholarPubMed
Nijmeijer, SW, Koelman, JH, Kamphuis, DJ, Tijssen, MA (2012). Muscle selection for treatment of cervical dystonia with botulinum toxin: a systematic review. Parkinsonism Relat Disord 18:731–736.CrossRefGoogle ScholarPubMed
Odergren, T, Hjaltason, H, Kaakkola, S, Solders, G, Hanko, J, Fehling, C, Marttila, RJ, Lundh, H, Gedin, S, Westergren, I, Richardson, A, Dott, C, Cohen, H (1998). A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6–12.CrossRefGoogle Scholar
Pappert, EJ, Germanson, T; Myobloc/Neurobloc European Cervical Dystonia Study (2008). Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23: 510–517.CrossRefGoogle ScholarPubMed
Patel, N, Hanfelt, J, Marsh, L, Jankovic, J; Members of the Dystonia Coalition (2014). Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry 85(8): 882–884.CrossRefGoogle ScholarPubMed
Poewe, W, Deuschl, G, Nebe, A, Feifel, E, Wissel, J, Benecke, R, Kessler, KR, Ceballos-Baumann, AO, Ohly, A, Oertel, W, Künig, G; German Dystonia Study Group (1998). What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64:13–17.CrossRefGoogle ScholarPubMed
Ramirez-Castaneda, J, Jankovic, J (2014). Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 90:344–348.CrossRefGoogle ScholarPubMed
Ramirez-Castaneda, J, Jankovic, J, Comella, C, Dashtipour, K, Fernandez, HH, Mari, Z (2013). Diffusion, spread, and migration of botulinum toxin. Mov Disord 28:1775–1783.CrossRefGoogle ScholarPubMed
Sankhla, C, Jankovic, J, Duane, D (1998). Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 13:150–154.CrossRefGoogle ScholarPubMed
Schramm, A, Baumer, T, Fietzek, U, Heitmann, S, Walter, U, Jost, WH (2015). Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. J Neural Transm 122:1457–1463.CrossRefGoogle ScholarPubMed
Sethi, KD, Rodriguez, R, Olayinka, B (2012). Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419–423.CrossRefGoogle ScholarPubMed
Simpson, DM, Blitzer, A, Brashear, A, Comella, C, Dubinsky, R, Hallett, M, Jankovic, J, Karp, B, Ludlow, CL, Miyasaki, JM, Naumann, M, So, Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2008). Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) – report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699–1706.Google Scholar
Simpson, DM, Hallet, M, Ashman, EJ, Cornella, CL, Green, MW, Gronseth, GS, Armstrong, MJ, Gloss, D, Potrebic, S, Jankovic, J, Karp, BP, Naumann, M, So, YT, Yablon, SA (2016). Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guidelines Development Subcommittee of the American Academy of Neurology. Neurology 86(19): 1818–1826.CrossRefGoogle Scholar
Thenganatt, MA, Fahn, S (2012). Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep 12:399–409.CrossRefGoogle ScholarPubMed
Thenganatt, MA, Jankovic, J (2014). Treatment of dystonia. Neurotherapeutics 11: 139–152.CrossRefGoogle ScholarPubMed
Truong, D, Duane, DD, Jankovic, J, Singer, C, Seeberger, LC, Comella, CL, Lew, MF, Rodnitzky, RL, Danisi, FO, Sutton, JP, Charles, PD, Hauser, RA, Sheean, GL (2005). Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20:783–791.Google Scholar
Truong, D, Brodsky, M, Lew, M, Brashear, A, Jankovic, J, Molho, E, Orlova, O, Timerbaeva, S; Global Dysport Cervical Dystonia Study Group (2010). Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316–323.CrossRefGoogle ScholarPubMed
Wu, C, Xue, F, Chang, W, Lian, Y, Zheng, Y, Xie, N, Zhang, L, Chen, C (2016). Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. Springerplus 8 (5):1292.CrossRefGoogle Scholar
Yun, JY, Kim, JW, Kim, HT, Chung, SJ, Kim, JM, Cho, JW, Lee, JY, Lee, HN, You, S, Oh, E, Jeong, H, Kim, YE, Kim, HJ, Lee, WY, Jeon, BS (2015). Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord 30:206–213.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×